WEGOVY® FLEXTOUCH® 1 mg is a once-weekly semaglutide injection used for chronic weight management in adults with obesity or overweight accompanied by weight-related medical conditions. The 1 mg dose represents an intermediate step in the titration schedule, designed to maintain steady progress in appetite control and weight reduction as patients transition toward therapeutic maintenance levels.

Key Benefits
• Mid-stage titration dose supporting continued adaptation to treatment
• Helps control appetite, cravings, and caloric intake
• Supports ongoing, clinically meaningful weight loss
• Convenient once-weekly dosing using the FLEXTOUCH® pen
• Prepares patients for escalation to higher doses for optimal results

How It Works
Semaglutide, the active ingredient in WEGOVY®, is a GLP-1 receptor agonist that mimics natural satiety hormones. It slows gastric emptying, reduces hunger signals, enhances feelings of fullness, and improves overall control of food intake. These effects lead to consistent, sustainable weight reduction when combined with lifestyle modifications.

Ideal Candidates
• Adults with obesity (BMI ≥30 kg/m²)
• Adults with overweight (BMI ≥27 kg/m²) and at least one associated condition (type 2 diabetes, hypertension, dyslipidaemia, etc.)
• Patients who have completed the 0.25 mg and 0.5 mg titration phases
• Individuals requiring ongoing metabolic support during dose escalation

Administration
Administered once weekly via the prefilled FLEXTOUCH® injector, subcutaneously in the abdomen, thigh, or upper arm.
The 1 mg dose is typically used for weeks 9–12 as part of the structured titration schedule. After this phase, patients generally advance to 1.7 mg or 2.4 mg depending on tolerance and clinical guidance.

Possible Side Effects
Common effects may include nausea, vomiting, diarrhoea, constipation, abdominal discomfort, or reduced appetite, particularly during dose adjustments.
Most symptoms lessen over time. Rare but potentially serious risks include pancreatitis, gallbladder issues, or severe gastrointestinal reactions. Monitoring by a qualified healthcare provider is essential.